Open Book Extracts announces completion of large RCT on effects of rare cannabinoids on pain

Photo © AdobeStock.com/contentdealer

Open Book Extracts (OBX; Roxboro, NC) has announced the completion of its first randomized, controlled trial on the effects of rare cannabinoids such as CBC and CBG on long-term pain, well-being, and quality of life. OBX did this with the assistance of Radicle Science, which conducted a four-week blinded, randomized, controlled, parallel-group comparison of various OBX formulations.

"We are excited to have partnered with OBX to conduct history's largest randomized, controlled trial of cannabinoids for pain, involving nearly 2,000 participants from across the U.S. This groundbreaking study also represents history's first randomized controlled trial on the synergistic impact of rare cannabinoids like CBC and CBG on pain,” said Jeff Chen, MD/MBA, co-founder, and chief executive officer of Radicle Science. “A majority of all phytocannabinoid clinical research has centered around THC, and we are uncovering the untapped potential in the other phytocannabinoids found in the cannabis and hemp plant."

Results from the study are expected in late April 2022. In the future, OBX and Radicle Science will launch the first large-scale, blinded, randomized, placebo-controlled clinical trials on rare cannabinoids including THCV, CBN, CBG, and CBC, to study their effects on energy, focus, appetite, sleep disturbance, stress, and anxiety across more than 10,000 study participants.

“Validating the therapeutic benefits of cannabinoids with scientifically-backed research is a source of great pride for our company,” said Dave Neundorfer, chief executive officer, for OBX. “We are on a quest to understand the true potential of cannabinoids and thank the Radicle Science team for providing a platform that supports the research that will help transform the CBD industry. The completion of this study is a key milestone in our research efforts and further demonstrates our commitment to scientific research and development for the cannabinoid industry as a whole.”